Publication Name	World Journal of Clinical Oncology
Manuscript ID	17159
Country	Spain

Received	2015-02-21 21:37
Peer-Review Started	2015-02-22 17:51
To Make the First Decision	2015-04-10 17:49
Return for Revision	2015-04-17 08:44
Revised	2015-05-08 15:46
Second Decision	2015-05-29 15:27
Accepted by Journal Editor-in-Chief	2015-05-30 00:04
Accepted by Executive Editor-in-Chief	2015-06-08 16:03
Articles in Press	2015-06-08 16:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-23 15:12
Publish the Manuscript Online	2015-08-17 16:41

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?
Manuscript Source	Invited Manuscript
All Author List	Edurne Arriola, Álvaro Taus and David Casadevall
Funding Agency and Grant Number
Corresponding Author	Dr. Edurne Arriola, Oncology Depart­ment, Hospital del Mar, Passeig Marítim de la Barceloneta, 25-29, 08003 Barcelona, Spain. earriola@parcdesalutmar.cat
Key Words	Non-small cell lung cancer; Tyrosine kinase inhibitors; Epidermal growth factor receptors
Core Tip	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are well established as the treatment of choice in EGFR-mutant non-small cell lung cancer. However, they are approved and have shown efficacy in patients with wild-type disease. Here, we review the clinical data showing this consistent benefit in a subgroup of patients and the potential biological mechanisms of this clinical effect.
Publish Date	2015-08-17 16:41
Citation	Arriola E, Taus A, Casadevall D. Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? World J Clin Oncol 2015; 6(4): 45-56
URL	http://www.wjgnet.com/2218-4333/full/v6/i4/45.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i4.45

Full Article (PDF)	WJCO-6-45.pdf
Full Article (Word)	WJCO-6-45.doc
Manuscript File	17159-Review.doc
Answering Reviewers	17159-Answering reviewers.pdf
Audio Core Tip	17159-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17159-Conflict-of-interest statement.pdf
Copyright License Agreement	17159-Copyright assignment.pdf
Peer-review Report	17159-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	17159-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17159-Scientific misconduct check.pdf
Scientific Editor Work List	17159-Scientific editor work list.pdf